Difference between revisions of "To do page"
Jump to navigation
Jump to search
m |
m |
||
| Line 6: | Line 6: | ||
*Add additional information to [[Consult topics in hematology and oncology]] | *Add additional information to [[Consult topics in hematology and oncology]] | ||
*Update [[Antiemesis]] page | *Update [[Antiemesis]] page | ||
| − | |||
*Add additional Factor VIII inhibitor regimens & references to [[Coagulopathies]] page: Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003 Apr;121(1):21-35. [http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2003.04162.x/abstract link to original article] | *Add additional Factor VIII inhibitor regimens & references to [[Coagulopathies]] page: Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003 Apr;121(1):21-35. [http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2003.04162.x/abstract link to original article] | ||
*Add RTOG 9910 to [[Prostate cancer]]: http://jco.ascopubs.org/content/early/2014/12/22/JCO.2014.58.0662.full | *Add RTOG 9910 to [[Prostate cancer]]: http://jco.ascopubs.org/content/early/2014/12/22/JCO.2014.58.0662.full | ||
| Line 12: | Line 11: | ||
*Add choriocarcinoma regimens to [[Germ cell tumors]] https://www.ncbi.nlm.nih.gov/pubmed/19370618 | *Add choriocarcinoma regimens to [[Germ cell tumors]] https://www.ncbi.nlm.nih.gov/pubmed/19370618 | ||
*Add LUX-Lung 3 and LUX-Lung 6 information to [[Non-small cell lung cancer]] http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2971173-8/abstract | *Add LUX-Lung 3 and LUX-Lung 6 information to [[Non-small cell lung cancer]] http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2971173-8/abstract | ||
| − | |||
*Disambiguate and link together induction and maintenance/consolidation for [[Chronic_lymphocytic_leukemia_(CLL)_and_Small_lymphocytic_lymphoma_(SLL)]], [[Diffuse_large_B-cell_lymphoma]], [[Mantle_cell_lymphoma]], and [[Multiple_myeloma]] | *Disambiguate and link together induction and maintenance/consolidation for [[Chronic_lymphocytic_leukemia_(CLL)_and_Small_lymphocytic_lymphoma_(SLL)]], [[Diffuse_large_B-cell_lymphoma]], [[Mantle_cell_lymphoma]], and [[Multiple_myeloma]] | ||
*Add arms A & B regimens from Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278-84. [http://annonc.oxfordjournals.org/content/24/9/2278.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23704196 PubMed] to [[breast cancer]] | *Add arms A & B regimens from Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278-84. [http://annonc.oxfordjournals.org/content/24/9/2278.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23704196 PubMed] to [[breast cancer]] | ||
| Line 26: | Line 24: | ||
*Alphabetize and verify regimens & references on [[Breast cancer]] page | *Alphabetize and verify regimens & references on [[Breast cancer]] page | ||
*Link all randomized trials together | *Link all randomized trials together | ||
| + | *Update [[Vesicant & irritant chemotherapy]] page | ||
| + | *Add HLH-2004 to [[Hemophagocytic lymphohistiocytosis (HLH)]] https://www.ncbi.nlm.nih.gov/pubmed/16937360 | ||
Revision as of 02:30, 27 April 2017
This page is a running list of tasks that should be done for HemOnc.org. Contributors can either add additional items to be done here, or come here to look for ways to contribute to the site. Please move things from the "to be done" to the "completed" section once it's been done.
To be done
- Add more Example chemotherapy order sets for all regimens
- Update information for all medications in the Drug index, e.g. package insert versions
- Add additional information to Consult topics in hematology and oncology
- Update Antiemesis page
- Add additional Factor VIII inhibitor regimens & references to Coagulopathies page: Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003 Apr;121(1):21-35. link to original article
- Add RTOG 9910 to Prostate cancer: http://jco.ascopubs.org/content/early/2014/12/22/JCO.2014.58.0662.full
- Add pre-chemotherapy hepatitis B flowchart
- Add choriocarcinoma regimens to Germ cell tumors https://www.ncbi.nlm.nih.gov/pubmed/19370618
- Add LUX-Lung 3 and LUX-Lung 6 information to Non-small cell lung cancer http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2971173-8/abstract
- Disambiguate and link together induction and maintenance/consolidation for Chronic_lymphocytic_leukemia_(CLL)_and_Small_lymphocytic_lymphoma_(SLL), Diffuse_large_B-cell_lymphoma, Mantle_cell_lymphoma, and Multiple_myeloma
- Add arms A & B regimens from Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278-84. link to original article PubMed to breast cancer
- Change efficacy to follow the guidelines from "Translating statistical findings into plain English".
- Add PMID 24428673, PMID 15939712, PMID 16467197, bexarotene for T-cell lymphoma
- Create a consistent level of evidence header for all non-randomized trials
- Verify all non-verified protocols
- Change "ICD-9 codes" to "ICD codes" and include ICD-10 codes
- Use Pinger or ExternalLinks extension to check for broken links on pages
Completed
- Disambiguate and link together induction and maintenance/consolidation for Follicular_lymphoma
- Alphabetize and verify regimens & references on Breast cancer page
- Link all randomized trials together
- Update Vesicant & irritant chemotherapy page
- Add HLH-2004 to Hemophagocytic lymphohistiocytosis (HLH) https://www.ncbi.nlm.nih.gov/pubmed/16937360